Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Lichtenberg

Showing results (31-40 of 92) with videos related to

Pageof 10
Sort By:
International Journal of Health Economics and Management|November 24, 2016
The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000-2011Frank R Lichtenberg
Journal of Pharmaceutical Policy and Practice|June 21, 2024
Do newer drugs treat fewer diseases, controlling for time since launch? Evidence from France and the U.SFrank R Lichtenberg
Disability and Health Journal|February 3, 2019
The impact of access to prescription drugs on disability in eleven European countriesFrank R Lichtenberg
Journal of Public Health (Oxford, England)|January 14, 2020
The impact of pharmaceutical innovation on the burden of disease in Ireland, 2000-2015Frank R Lichtenberg
Economics and Human Biology|September 24, 2025
The impact of biomedical innovation on cancer mortality in 37 countries, 2003-2017Frank R Lichtenberg
Expert Review of Pharmacoeconomics & Outcomes Research|April 29, 2026
The relationship between changes in prescription drug sales and changes in mortality and hospital utilization in Denmark, 2005-2019Frank R Lichtenberg
Health Economics|May 14, 2021
Are drug prices subject to creative destruction? Evidence from the US, 1997-2017Frank R Lichtenberg
The American Journal of Managed Care|February 11, 2005
The effect of access restrictions on the vintage of drugs used by Medicaid enrolleesFrank R Lichtenberg
Forum for Health Economics & Policy|August 30, 2022
The Impact of Biopharmaceutical Innovation on Disability, Social Security Recipiency, and Use of Medical Care of U.S. Community Residents, 1998-2015Frank R Lichtenberg
Nature Medicine|March 9, 2011
Despite steep costs, payments for new cancer drugs make economic senseFrank R Lichtenberg
Pageof 10

Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
International Journal of Health Economics and Management|November 24, 2016
The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000-2011Frank R Lichtenberg
Journal of Pharmaceutical Policy and Practice|June 21, 2024
Do newer drugs treat fewer diseases, controlling for time since launch? Evidence from France and the U.SFrank R Lichtenberg
Disability and Health Journal|February 3, 2019
The impact of access to prescription drugs on disability in eleven European countriesFrank R Lichtenberg
Journal of Public Health (Oxford, England)|January 14, 2020
The impact of pharmaceutical innovation on the burden of disease in Ireland, 2000-2015Frank R Lichtenberg
Economics and Human Biology|September 24, 2025
The impact of biomedical innovation on cancer mortality in 37 countries, 2003-2017Frank R Lichtenberg
Expert Review of Pharmacoeconomics & Outcomes Research|April 29, 2026
The relationship between changes in prescription drug sales and changes in mortality and hospital utilization in Denmark, 2005-2019Frank R Lichtenberg
Health Economics|May 14, 2021
Are drug prices subject to creative destruction? Evidence from the US, 1997-2017Frank R Lichtenberg
The American Journal of Managed Care|February 11, 2005
The effect of access restrictions on the vintage of drugs used by Medicaid enrolleesFrank R Lichtenberg
Forum for Health Economics & Policy|August 30, 2022
The Impact of Biopharmaceutical Innovation on Disability, Social Security Recipiency, and Use of Medical Care of U.S. Community Residents, 1998-2015Frank R Lichtenberg
Nature Medicine|March 9, 2011
Despite steep costs, payments for new cancer drugs make economic senseFrank R Lichtenberg
Pageof 10